|
Click on
below links to read more on Trans D
More
Information on Trans D Tropin Below: SUMMARY
One of the frontiers
of current medical science is the challenge of slowing
down the process of aging in an
effort to prolong life and combat the debilitation caused by
aging-related disorders. In this
arena, human growth hormone (GH) therapy has gained both
prominence and
notoriety.
The natural decline of growth hormone levels with age has
provided a rationale for anti-aging
therapies that are based on regenerating growth hormone levels in
the body.
However, treatment using recombinant growth hormone has been
criticized for its enhanced cancer risk,
primarily through its potential to increase concentrations of its
hepatic metabolite, IGF-1 (insulin-like
growth factor 1) to physiologically harmful levels. IGF-1 is
an antiapoptotic promoter of cellular
proliferation, and is present in high concentrations
during the initial stages of
cancer.
A clear need, therefore, exists for GH-based therapies that
address this important safety concern,
accompanied with detailed clinical validation.
Trans-D Tropin® (TDT) is a transdermally administered analog of
growth hormone releasing hormone (GHRH).
GHRH is manufactured in the hypothalamus, and is the natural
stimulant that promotes human growth
hormone release from the pituitary. Through its mimicry of
GHRH,
TDT indirectly boosts endogenous growth hormone production,
vastly improving on the efficacy and
safety when compared to recombinant growth hormone therapy. In an effort
to quantify the remarkable properties of
TDT in humans, a series of clinical trials have been conducted as follows:
• A pilot study on 30 patients that
studies several subjective
parameters.
• A small
clinical study on 53 patients that evaluates the efficacy of GH release
and suppression of IGF-1
production.
• An 8-week
long exhaustive, multi-centered, double blind, placebo-controlled clinical
study on 117 patients that measures GH
release, IGF-1 suppression and several other biochemical/hematological
parameters.
These clinical studies have
shed light on the ability of TDT to maintain sustained
growth hormone release at optimum
physiological concentrations, while simultaneously
suppressing the levels of IGF-1. This has
broken through the commonly held paradigm that high serum
GH leads to increased levels of IGF-1. It
should be noted that the high GH and low IGF-1
levels prevalent in youth,
naturally and inversely change to low GH and high IGF-1 levels with
the progress of age.
Trans-D Tropin®
seeks to reverse that trend, and brings us one step closer
to the proverbial “fountain of
youth”.
|